Diffuse Large B-Cell Lymphoma Test Your Knowledge

Test Your Knowledge

Quiz: Does High-Dose Methotrexate Have Better CNS Relapse Control in DLBCL?

02/25/2022

True or false: A multicenter analysis has clarified that high-dose methotrexate is associated with better CNS relapse control, but only for high-risk patients with DLBCL.

True or false: A multicenter...

02/25/2022

Oncology

Test Your Knowledge

Quiz: Is Post-ASCT Pembrolizumab Therapy Associated With Elevated Circulating DCs for cHL, DLBCL?

02/11/2022

True or false: Post-ASCT pembrolizumab maintenance therapy is associated with a persistent elevation of circulating DCs in patients with cHL and DLBCL.

True or false: Post-ASCT...

02/11/2022

Oncology

Test Your Knowledge

Quiz: Is Polatuzumab Vedotin a Salvage Option for R/R DLBCL?

02/07/2022

True or false: Polatuzumab vedotin combined with either bendamustine-rituximab or other intensive chemotherapy is not an effective salvage option for patients with R/R DLBCL.

True or false: Polatuzumab...

02/07/2022

Oncology

Test Your Knowledge

Quiz: Is EFS a Surrogate Endpoint for OS for Refractory LBCL?

01/31/2022

True or false: Data from a pivotal study on axicabtagene ciloleucil supports the use of EFS as a surrogate endpoint for long-term OS in refractory LBCL.

True or false: Data from a...

01/31/2022

Oncology

Quiz

Quiz: Will the S1918 Trial Impact the Standard of Care in DLBCL?

01/28/2022

True or false: The S1918 study has the potential to change the standard of care for patients with DLBCL.

True or false: The S1918 study...

01/28/2022

Oncology

Test Your Knowledge

Quiz: Do CD19-7x19 CAR-T Cells Plus Anti-PD-1 Antibody Show Feasibility in Patients With R/R DLBCL?

01/27/2022

True or false: Preliminary data from a phase 1b trial found CD19-7x19 CAR-T cells combined with an anti-PD-1 antibody shows feasibility in patients with R/R DLBCL.

True or false: Preliminary data...

01/27/2022

Oncology

Test Your Knowledge

Quiz: SWOG Trials Highlight Extranodal Presentation in Limited Stage DLBCL

12/22/2021

Fill in the blank: Patients with LS DLBCL treated on 3 SWOG studies had ______ PFS and OS, regardless of extranodal versus nodal presentation.

Fill in the blank: Patients with...

12/22/2021

Oncology

Test Your Knowledge

Quiz: Rituximab Plus Chemo Approved for Which Type of Cancer?

12/20/2021

In December 2021, the FDA approved the combination of rituximab plus chemotherapy for previously untreated pediatric patients with advanced stage CD20-positive DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

In December 2021, the FDA...

12/20/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment Received FDA Approved for Certain Pediatric Cancers?

12/03/2021

The FDA recently approved which of the following treatments for pediatric patients with advanced stage CD20+ DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

The FDA recently approved which...

12/03/2021

Oncology

Test Your Knowledge

Quiz: What is the Expected OS Rate of Patients With R/R DLBCL?

12/02/2021

True or false: 95% of patients with R/R DLBCL who have received 2 or more lines of prior therapy have an expected OS of more than 2 years.

True or false: 95% of patients...

12/02/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology